2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1116

Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1139

Management of Gout – a Survey for Healthcare Providers in South Australia

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1124

Marked Variability of Circulating Urate Concentrations in Banked Samples Based on Sample Type and Assay

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 1310

Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1044

Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis

Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1403

Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 998

Mental Health in Patients with Axial Spondyloarthritis: Increasing Our Understanding of the Disease. Results from the Spanish Atlas

Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1724

Metabolic Regulation of Fibrosis in Systemic Sclerosis: The CD38-NAD+ Link

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 1406

Methods for Generating Multiple High-Dimensional Analyses of Cryopreserved Synovial Tissue Developed By the Accelerating Medicines Partnership RA/SLE Network

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1572

MHC Associations of Ankylosing Spondylitis in East Asians Are Driven By HLA-B Amino-Acid Position 97, Confirming Findings in European Descent Subjects

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II

9:00AM-11:00AM: Abstract Number: 1712

Microbial and Metabolic MULTI-Omic Correlations in Systemic Sclerosis Patients

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 1351

Minimal Clinically Important Improvement (MCII) of RAPID3 (ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3), an INDEX of ONLY Patient Self-Report Scores in Rheumatoid Arthritis (RA): Similar Performance to DAS28 and CDAI

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1715

Mitochondrial DNA Mutations and Respiratory Chain Dysfunction in Lung Fibrosis of Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 1011

Mitochondrial Haplogroups-Mediated Methylation Regulates Apoptosis in Osteoathritis Cartilage

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1417

Mitophagy Defect in Fibroblast-like Synoviocytes of Rheumatoid Arthritis Is Improved By Pyruvate Treatment

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].